Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))

Roman V. Uzhachenko, Vijaya Bharti, Zhufeng Ouyang, Ashlyn Blevins, Stacey Mont, Nabil Saleh, Hunter A. Lawrence, Chengli Shen, Sheau Chiann Chen, Gregory D. Ayers, David G. DeNardo, Carlos Arteaga, Ann Richmond, Anna E. Vilgelm

Research output: Contribution to journalComment/debatepeer-review

Abstract

(Cell Reports 35, 108944-1–16.e1–e6; April 6, 2021) Carlos Arteaga receives or has received research grants from Pfizer, Lilly, and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. None of these relationships are relevant to the work published in this manuscript. This information was inadvertently omitted during the preparation of the manuscript but now appears with the article online. The authors regret this error.

Original languageEnglish (US)
Article number109271
JournalCell Reports
Volume35
Issue number12
DOIs
StatePublished - Jun 22 2021

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))'. Together they form a unique fingerprint.

Cite this